{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:53Z","timestamp":1756902173612,"version":"3.44.0"},"reference-count":14,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Despite a boxed warning, postmarketing reports of deferasirox-associated hepatic injury in patients with chronic transfusions are not well described. Hepatic impairment, including failure, has been reported to occur more frequently in patients older than 55 years and in those with significant comorbidities, including liver cirrhosis and multiorgan failure. In this case report, we describe significant hyperbilirubinemia and acute hepatocellular jaundice related to deferasirox in a 7-year-old female being treated for iron overload secondary to chronic transfusions. This report outlines a unique case without preexisting risk factors in which other causes of liver injury are excluded as defined by the Roussel Uclaf Causality Assessment Method, which indicates a probable score of deferasirox causing the injury.<\/jats:p>","DOI":"10.5863\/1551-6776-23.1.64","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T19:10:59Z","timestamp":1519240259000},"page":"64-67","source":"Crossref","is-referenced-by-count":1,"title":["Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report"],"prefix":"10.5863","volume":"23","author":[{"given":"Elizabeth A.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarabeth","family":"Wojnowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Seabury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"12","key":"i1551-6776-23-1-64-b1","series-title":"Am J Hematol","first-page":"1128","article-title":"Mechanisms of iron loading and toxicity","volume":"82","year":"2007","unstructured":"Anderson\n              GJ.\n            \n          \n          Mechanisms of iron loading and toxicity. Am J Hematol. 2007;82(12):1128\u20131131"},{"issue":"8","key":"i1551-6776-23-1-64-b2","series-title":"Clin Pharmacokinet","first-page":"679","article-title":"Clinical pharmacology of deferasirox","volume":"53","year":"2014","unstructured":"Tanaka\n              C.\n            \n          \n          Clinical pharmacology of deferasirox. Clin Pharmacokinet. 2014;53(8):679\u2013694."},{"year":"2016","series-title":"Jadenu [package insert]","key":"i1551-6776-23-1-64-b3","unstructured":"Jadenu [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016."},{"issue":"3","key":"i1551-6776-23-1-64-b4","series-title":"Hematol Rep","first-page":"5987","article-title":"Acute liver failure in a pediatric patient with congenital dysery-thropoietic anemia type I treated with deferasirox","volume":"7","year":"2015","unstructured":"Ling\n              G\n            , PinskV, Golan-TriptoI, \n          et al. Acute liver failure in a pediatric patient with congenital dysery-thropoietic anemia type I treated with deferasirox. Hematol Rep. 2015;7(3):5987."},{"issue":"3","key":"i1551-6776-23-1-64-b5","series-title":"J Pediatr Hematol Oncol","first-page":"235","article-title":"Fulminant liver failure in a child with [beta]-thalassemia on deferasirox: a case report","volume":"39","year":"2016","unstructured":"Ramaswami\n              A\n            , RosenDJ, ChuJ, \n          et al. Fulminant liver failure in a child with [beta]-thalassemia on deferasirox: a case report. J Pediatr Hematol Oncol. 2016;39(3):235\u2013237."},{"issue":"3","key":"i1551-6776-23-1-64-b6","series-title":"J Pediatr Hematol Oncol","first-page":"217","article-title":"Acute liver failure during deferasirox chelation: a toxicity worth considering","volume":"39","year":"2017","unstructured":"Menaker\n              N\n            , HalliganK, ShurN, \n          et al. Acute liver failure during deferasirox chelation: a toxicity worth considering. J Pediatr Hematol Oncol. 2017;39(3):217\u2013222."},{"issue":"3","key":"i1551-6776-23-1-64-b7","series-title":"Br J Haematol","first-page":"501","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","year":"2007","unstructured":"Vichinsky\n              E\n            , OnyekwereO, PorterJ, \n          et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501\u2013508."},{"issue":"8","key":"i1551-6776-23-1-64-b8","series-title":"J Coll Physicians Surg Pak","first-page":"551","article-title":"Deferasirox induced liver injury in haemochromatosis","volume":"20","year":"2010","unstructured":"Aslam\n              N\n            , MettuP, Marsano-ObandoLS, \n          et al. Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg Pak. 2010; 20(8):551\u2013553."},{"issue":"9","key":"i1551-6776-23-1-64-b9","series-title":"Leuk Res","first-page":"1143","article-title":"Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study","volume":"34","year":"2010","unstructured":"Gattermann\n              N\n            , FinelliC, PortaMD, \n          et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143\u20131150."},{"issue":"1","key":"i1551-6776-23-1-64-b10","series-title":"Mediterr J Hematol Infect Dis","first-page":"e2014025","article-title":"Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy","volume":"6","year":"2014","unstructured":"Soliman\n              A\n            , YassinM, Al YafeiF, \n          et al. Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014025."},{"issue":"5","key":"i1551-6776-23-1-64-b11","series-title":"PLoS One","first-page":"e64114","article-title":"Pharmacogenetic study of deferasirox, an iron chelating agent","volume":"8","year":"2013","unstructured":"Lee\n              JW\n            , KangHJ, ChoiJY, \n          et al. Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One. 2013;8(5):e64114."},{"issue":"2","key":"i1551-6776-23-1-64-b12","series-title":"Eur J Clin Pharmacol","first-page":"247","article-title":"Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis","volume":"72","year":"2016","unstructured":"Marano\n              M\n            , BottaroG, GoffredoB, \n          et al. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. Eur J Clin Pharmacol. 2016;72(2):247\u2013248."},{"issue":"3","key":"i1551-6776-23-1-64-b13","series-title":"J Hepatol","first-page":"683","article-title":"Causality assessment methods in drug induced liver injury: strengths and weaknesses","volume":"55","year":"2011","unstructured":"Garcia-Cortes\n              M\n            , StephensC, LucenaMI, \n          et al. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55(3):683\u2013691."},{"key":"i1551-6776-23-1-64-b14","unstructured":"US National Library of Medicine. \n          Roussel Uclaf Causality Assessment Method (RUCAM) in drug induced liver injury. https:\/\/livertox.nih.gov\/rucam.html. Accessed December 14, 2016.","article-title":"Roussel Uclaf Causality Assessment Method (RUCAM) in drug induced liver injury"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/1\/article-p64.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/23\/1\/64\/1782537\/1551-6776-23_1_64.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/1\/article-p64.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/1\/article-p64.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:34:49Z","timestamp":1747355689000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/1\/article-p64.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":14,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-23.1.64","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2018]]}}}